Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: Case report

Incecik F., Oenlen Y., OEZCAN K.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, vol.27, no.5, pp.797-799, 2007 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 5
  • Publication Date: 2007
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.797-799
  • Çukurova University Affiliated: Yes


Recombinant hepatitis B vaccine, which is used throughout the world, rarely has systemic adverse events like polyradiculoneuritis, demyelination of central nervous system. otoimmune hemolytic anemia and immune thrombocytopenia, as well as local side effects. We diagnosed thrombocytopenic purpura in a 10 months-old case, which developed 3 weeks after the 3(rd) dose of the recombinant hepatitis B vaccine. There was no drug history or prior infection. Clinical and laboratory findings of autoimmune or malignant disorders were negative and the bone marrow aspirate was normal. We presented this case to emphasize that thrombocytopenia may develop after recombinant hepatitis B vaccine and thus Should be taken into consideration.